大行评级｜花旗：对华润医疗开启30天下行催化观察目标价为7港元花旗发表报告，对华润医疗开启30天下行催化观察，预计公司上半年业绩将令市场失望，主要受以下因素拖累，包括淮阴医院潜在减值；

格隆汇07-26

大行评级｜花旗：对华润医疗开启30天下行催化观察目标价为7港元花旗发表报告，对华润医疗开启30天下行催化观察，预计公司上半年业绩将令市场失望，主要受以下因素拖累，包括淮阴医院潜在减值；华润健康(辽宁)收入增长较预期缓慢。该行预期华润医疗股价将对业绩压力作出负面反应，目标价为7港元，评级“买入”。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2454367004?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-26 14:21","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2454367004","market":"hk","top_or_hot":-1,"title":"大行评级｜花旗：对华润医疗开启30天下行催化观察 目标价为7港元花旗发表报告，对华润医疗开启30天下行催化观察，预计公司上半年业绩将令市场失望，主要受以下因素拖累，包括淮阴医院潜在减值；","media":"格隆汇","content":"<div>\n<p>大行评级｜花旗：对华润医疗开启30天下行催化观察 目标价为7港元花旗发表报告，对华润医疗开启30天下行催化观察，预计公司上半年业绩将令市场失望，主要受以下因素拖累，包括淮阴医院潜在减值；华润健康(辽宁)收入增长较预期缓慢。该行预期华润医疗股价将对业绩压力作出负面反应，目标价为7港元，评级“买入”。</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-26 14:21 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/rss/live/live.xml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>大行评级｜花旗：对华润医疗开启30天下行催化观察 目标价为7港元花旗发表报告，对华润医疗开启30天下行催化观察，预计公司上半年业绩将令市场失望，主要受以下因素拖累，包括淮阴医院潜在减值；华润健康(辽宁)收入增长较预期缓慢。该行预期华润医疗股价将对业绩压力作出负面反应，目标价为7港元，评级“买入”。</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0098860793.USD","symbol_name":"FRANKLIN INCOME \"A\" INC","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2454367004","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454367004","pubTimestamp":1721974869,"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"大行评级｜花旗：对华润医疗开启30天下行催化观察 目标价为7港元花旗发表报告，对华润医疗开启30天下行催化观察，预计公司上半年业绩将令市场失望，主要受以下因素拖累，包括淮阴医院潜在减值；华润健康(辽宁","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4588":"碎股","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","BK1570":"华润系","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4207":"综合性银行","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0106831901.USD":"贝莱德世界金融基金A2","BK4504":"桥水持仓","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","01515":"华润医疗","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK1209":"保健护理机构","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","BK4566":"资本集团","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC"},"translate_title":"Big Bank Ratings | Citigroup: The target price of 30-day downward catalytic observation for China Resources Medical is HK $7. Citigroup issued a report and opened a 30-day downward catalytic observation for China Resources Medical. It is expected that the company's performance in the first half of the year will disappoint the market, mainly dragged down by the following factors, including potential impairment of Huaiyin Hospital;","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01515":1},"content_text":"大行评级｜花旗：对华润医疗开启30天下行催化观察 目标价为7港元花旗发表报告，对华润医疗开启30天下行催化观察，预计公司上半年业绩将令市场失望，主要受以下因素拖累，包括淮阴医院潜在减值；华润健康(辽宁)收入增长较预期缓慢。该行预期华润医疗股价将对业绩压力作出负面反应，目标价为7港元，评级“买入”。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454367004"}

大行评级｜花旗：对华润医疗开启30天下行催化观察 目标价为7港元花旗发表报告，对华润医疗开启30天下行催化观察，预计公司上半年业绩将令市场失望，主要受以下因素拖累，包括淮阴医院潜在减值；

精彩评论

大行评级｜花旗：对华润医疗开启30天下行催化观察目标价为7港元花旗发表报告，对华润医疗开启30天下行催化观察，预计公司上半年业绩将令市场失望，主要受以下因素拖累，包括淮阴医院潜在减值；